Could a common blood thinner protect the brain after a burst aneurysm?
NCT ID NCT07493577
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called tirofiban (Aggrastat) in 82 people who have had bleeding from a brain aneurysm. The drug is given through a vein to prevent blood clots that can cause delayed brain damage. The main goal is to find the safest dose, while also checking if it reduces complications like vasospasm and improves recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tirofiban (Aggrastat), a blood-thinning drug given intravenously
What this could lead to
If it works, this could point toward a treatment to reduce delayed brain injury after aneurysm bleeding.
What could go wrong
This is an early, small trial (82 people) focused on safety and dosing. The drug may not improve outcomes and carries bleeding risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEURYSMAL SUBARACHNOID HEMORRHAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke University Health System
Durham, North Carolina, 27710, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Texas Health Sciences Center
Houston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••